Eli Lilly reached a market valuation above $1 trillion after sustained gains tied to its obesity and metabolic medicines. The milestone marks the first time a pharmaceutical company has crossed the trillion‑dollar threshold, reflecting outsized investor returns from weight‑loss therapeutics and related sales momentum. The valuation underscores how high‑growth obesity drugs have reshaped biopharma market dynamics and investor expectations for drug franchises that combine therapeutic and broad public‑health demand.